French plant transfers to Vectura Group as Aenova's lease ends

By Dan Stanton contact

- Last updated on GMT

French plant transfers to Vectura Group as Aenova's lease ends
Aenova’s lease of a manufacturing plant in France has ended and the facility has been transferred back to SkyePharma, now part of the Vectura Group.

Contract development and manufacturing organisation (CDMO) Aenova inked a lease on SkyePharma’s tablet production site in Lyon, France back in 2011​, and two years later​ renewed the contract.

But the lease expired last week and the facility has transferred back to its owners, Vectura Group who only last month completed its $620m acquisition of fellow respiratory drugmaker SkyePharma.

“We are very pleased that the Lyon facility returns to the Group at this exciting time​,” said Vectura’s EVP of Oral Business, David Lescuyer.

“We have a strong high quality base with the return of the Facility and we are confident of growing the business and creating future value by working with existing and new partners and leveraging our proven innovation and technology.”

The site itself makes seven of Vectura/SkyePharma’s oral products based on the firm’s proprietary delivery technologies.

It was also an access to such complex tableting technologies for Aenova which said it intended to offer the excess capacity to bolster its solid dosage form capacity in Europe back in 2011.

Whether any existing contracts will continue at Lyon now Aenova has left is unknown, but since it began leasing the plant the firm has upped its own internal manufacturing network through various mergers and acquisitions.

In October 2012​, the CDMO took over Germany’s Temmler Group, which added seven production sites in Germany, Switzerland, Italy and Ireland.

And the following year​ the firm increased its network from eight to 21 sites through the acquisition of Haupt Pharma.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us


View more